PMID- 29063073
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2095-882X (Print)
IS  - 2589-0514 (Electronic)
IS  - 2095-882X (Linking)
VI  - 3
IP  - 3
DP  - 2017 Sep
TI  - The association between metformin use and colorectal cancer survival among 
      patients with diabetes mellitus: An updated meta-analysis.
PG  - 169-175
LID - 10.1016/j.cdtm.2017.06.001 [doi]
AB  - OBJECTIVE: Recent studies have reported conflicting results on the correlation 
      between metformin use and outcomes in patients with colorectal cancer (CRC). A 
      meta-analysis was performed to evaluate the efficacy of metformin therapy on the 
      prognosis of CRC patients with type 2 diabetes mellitus (T2DM). METHODS: We 
      conducted a systematic search of PubMed, EMBASE, the Cochrane Library, and the 
      Web of Science for related articles up to August 2016. Two investigators 
      independently identified and extracted information. Pooled risk estimates [hazard 
      ratios (HRs)] and 95% confidence intervals (CIs) were calculated using 
      fixed-effects models. The risk of publication bias was assessed by examining 
      funnel plot asymmetry as well as Egger's test and Begg's test. RESULTS: Of 81 
      articles identified, 8 retrospective cohort studies, representing 6098 cases of 
      CRC patients with T2DM who used metformin and 4954 cases of CRC patients with 
      T2DM who did not use metformin, were included in this meta-analysis. There was no 
      significant heterogeneity and quality difference between studies. Metformin users 
      had significantly improved overall survival (OS) (HR = 0.82, 95% CI: 0.77-0.87, 
      P = 0.000). However, Metformin use cannot affect CRC-specific survival 
      (HR = 0.84, 95% CI: 0.69-1.02, P = 0.079) compared to non-users. CONCLUSION: This 
      meta-analysis suggests that metformin use may improve survival among CRC patients 
      with T2DM. However, prospective controlled studies are still needed to rigorously 
      evaluate the efficacy of metformin as an anti-tumor agent.
FAU - Tian, Shan
AU  - Tian S
AD  - Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 
      430060, China.
FAU - Lei, Hong-Bo
AU  - Lei HB
AD  - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, 
      China.
FAU - Liu, Yu-Lan
AU  - Liu YL
AD  - Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 
      430060, China.
FAU - Chen, Yan
AU  - Chen Y
AD  - Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 
      430060, China.
FAU - Dong, Wei-Guo
AU  - Dong WG
AD  - Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 
      430060, China.
LA  - eng
PT  - Journal Article
DEP - 20170713
PL  - United States
TA  - Chronic Dis Transl Med
JT  - Chronic diseases and translational medicine
JID - 101679934
PMC - PMC5643786
OTO - NOTNLM
OT  - Anti-tumor agent
OT  - Colorectal cancer
OT  - Meta-analysis
OT  - Metformin
OT  - Survival
EDAT- 2017/10/25 06:00
MHDA- 2017/10/25 06:01
PMCR- 2017/07/13
CRDT- 2017/10/25 06:00
PHST- 2016/11/26 00:00 [received]
PHST- 2017/10/25 06:00 [entrez]
PHST- 2017/10/25 06:00 [pubmed]
PHST- 2017/10/25 06:01 [medline]
PHST- 2017/07/13 00:00 [pmc-release]
AID - S2095-882X(16)30131-1 [pii]
AID - 10.1016/j.cdtm.2017.06.001 [doi]
PST - epublish
SO  - Chronic Dis Transl Med. 2017 Jul 13;3(3):169-175. doi: 
      10.1016/j.cdtm.2017.06.001. eCollection 2017 Sep.